Breast Cancer Trialists Early .2005 .Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet, 365(9472) : 1687-1717.
Cardoso F.,Loibl S.,Pagani O.,Graziottin A.,Panizza P.,Martincich L.,Harbeck N. .2012 .The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European Journal of Cancer, 48(18) : 3355-3377.
Piccart-Gebhart M. J.,Procter M.,Leyland-Jones B.,Goldhirsch A.,Untch M.,Smith I.,Gelber R. D. .2005 .Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16) : 1659-1672.
Cameron D.,Piccart-Gebhart M. J.,Gelber R. D.,Procter M.,Goldhirsch A.,de Azambuja A.,Jackisch C. .2017 .11 years' followup of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet, 389(10075) : 1195-1205.
Dalmau E.,Armengol-Alonso A.,Munoz M.,Seguí-Palmer M. Á. .2014 .Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. The Breast, 23(6) : 710-720.
Cognetti F.,Naso G. .2021 .The clinician's perspective on the 21-gene assay in early breast cancer. Oncotarget, 12(26) : 2514.
Cuzick J.,Sestak I.,Baum M.,Buzdar A.,Howell A.,Dowsett M.,Forbes J. F. .2010 .Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet Oncology, 11(12) : 1135-1141.
Barron T. I.,Cahir C.,Sharp L.,Bennett K. .2013 .A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. British Journal of Cancer, 109(6) : 1513-1521.
Davies C.,Pan H.,Godwin J.,Gray R.,Arriagada R.,Raina V.,Peto R. .2013 .Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptorpositive breast cancer: ATLAS, a randomised trial. The Lancet, 381(9869) : 805-816.
Davies C.,Pan H.,Godwin J.,Gray R.,Arriagada R.,Raina V.,Peto R. .2013 .Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptorpositive breast cancer: ATLAS, a randomised trial. The Lancet, 381(9869) : 805-816.
Petrelli F.,Coinu A.,Cabiddu M.,Ghilardi M.,Lonati V.,Barni S. .2013 .Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Research and Treatment, 140 : 233-240.
Goss P. E.,Muss H. B.,Ingle J. N.,Whelan T. J.,Wu M. .2008 .Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clinical Breast Cancer, 8(5) : 411-417.
Bartlett J. M. S.,Sgroi D. C.,Treuner K.,Zhang Y.,Ahmed I.,Piper T.,Rea D. W. .2019 .Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More?(aTTom) trial. Annals of Oncology, 30(11) : 1776-1783.
Akbari M. E.,Delshad B.,Mousavizadeh M. .2020 .Outcomes of Breast Conservation Surgery and Modified Radical Mastectomy After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. International Journal of Cancer Management, 13(2) : 345-348.
Nichol A. M.,Chan E. K.,Lucas S.,Smith S. L.,Gondara L.,Speers C.,Tyldesley S. .2017 .The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. International Journal of Radiation Oncology* Biology* Physics, 98(4) : 829-839.
Bense R. D.,Qiu S. Q.,de Vries E. G.,Schröder C. P.,Fehrmann R. S. .2018 .Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. Cancer Treatment Reviews, 70 : 118-126.
Jinih M.,Relihan N.,Corrigan M. A.,O'Reilly S.,Redmond H. P. .2017 .Extended adjuvant endocrine therapy in breast cancer: evidence and update-a review. The Breast Journal, 23(6) : 694-705.
Cianfrocca M. .2008 .Overcoming recurrence risk: extended adjuvant endocrine therapy. Clinical Breast Cancer, 8(6) : 493-500.
Neri A.,Marrelli D.,Rossi S.,De Stefano A.,Mariani F.,De Marco G.,Roviello F. .2007 .Breast cancer local recurrence: risk factors and prognostic relevance of early time to recurrence. World Journal of Surgery, 31 : 36-45.
van Maaren M. C.,de Munck L.,Strobbe L. J.,Sonke G. S.,Westenend P. J.,Smidt M. L.,Siesling S. .2019 .Ten-year recurrence rates for breast cancer subtypes in The Netherlands: a large population-based study. International Journal of Cancer, 144(2) : 263-272.
Lu Y.,Chen Y.,Zhu L.,Cartwright P.,Song E.,Jacobs L.,Chen K. .2019 .Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Annals of Surgical Oncology, 26 : 1263-1275.
Chalela P.,Munoz E.,Inupakutika D.,Kaghyan S.,Akopian D.,Kaklamani V.,Ramirez A. .2018 .Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications, 12 : 109-115.
Krauss K.,Stickeler E. .2020 .Endocrine therapy in early breast cancer. Breast Care, 15(4) : 337-346.